Keywords:
ischemic heart failure, HFrEF, dobutamine stress echocardiography, myocardial viability, contractile reserve.References
1. Babes EE, Tit DM, Bungau AF, et al. Myocardial Viability Testing in the Management of Ischemic Heart Failure. Life (Basel). 2022;12(11):1760. doi:10.3390/life12111760.
2. Heusch G. Myocardial stunning and hibernation revisited. Nat Rev Cardiol. 2021; 18(7):522–536. doi:10.1038/s41569-021-00506-7.
3. Katikireddy CK, Samim A. Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy. Clin Cardiol. 2022;45(2):152–161. doi:10.1002/clc.2 3779.
4. Kheiri B, et al. The Utility of Low-Dose-Dobutamine Stress Echocardiography in Patients with Heart Failure with Reduced Ejection Fraction: An Update. J Clin Med. 2023.
5. Kourek C, et al. Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium. Int J Mol Sci. 2024;25(6):3113. doi:10.3390/ijms25063113.
6. Kwon DH, et al. Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy. Clin Cardiol. 2022;45:152–161.
7. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488–504. doi:10.1001/jama.2020.10262
8. Panza JA, Chrzanowski L, Bonow RO. Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;78(10):1068–1077. doi:10.1016/j.jacc.2021.07.004
9. Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, et al. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021;8:75449
